My research revolves around utilizing cutting-edge techniques such as large-scale molecular docking and enhanced molecular dynamics simulations to pinpoint new inhibitors for anticancer targets. In addition I am translating promising virtual hits into tangible molecules through organic synthesis for further biological screening. 

My research focus encompasses the development of novel therapeutic interventions for infectious diseases, particularly malaria and tuberculosis. Presently, I am engaged in the strategic design of hybrid compounds tailored to target malaria-causing Plasmodium parasites. This endeavor is specifically geared towards addressing the challenge posed by resistant strains of Plasmodium. 

My research interest lies in understanding the anticancer mechanism of the newly developed hybrid molecules in Dr. Sundriyal's lab using various biological techniques.

My research focuses on developing quinazoline-based inhibitors to treat Malaria. It combines computational methods like Homology Modeling, Virtual Screening, and MD Simulation with wet lab synthesis using advanced organic chemistry. Through this multidisciplinary approach, I aim to create effective anti-malarial compounds to combat malaria.

Currently, I'm involved in the development of zeolite-encapsulated small-molecule epigenetic modulators to combat cancer and drug resistance. This approach integrates synthetic chemistry, computational modeling, and innovative encapsulation techniques for enhanced efficacy and controlled release.